SRRK
Scholar RockCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Positive clinical readouts and a constructive partnership or commercial update validate the mechanism and could re-rate shares toward the analyst high (63.0). Limited near-term dilution and clear regulatory progress would reinforce upside within 12 months.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.9.
What can break
Clinical trial failure or missed endpoints
Momentum
61
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $50.34 · Bull $63.00 · Bear $42.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-04 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $60.29
Why
Momentum61 · Δ7d +12.4
Value41 · Δ7d -0.0
Sentiment53 · Δ7d +4.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
61
26% active weight
Current posture
7d trendSoftening
Δ7d
+12.4
Δ21d
+16.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
53
34% active weight
Current posture
7d trendImproving
Δ7d
+4.9
Δ21d
+5.7
Why this grade
Composite grade C. Momentum 60.9 / Value 41.1 / Sentiment 52.6
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$6.1B
Beta
0.69
Shares Out
119.83M
P/E (TTM) · Derived
-15.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-19.06
Rev YoY
-100.0%
EPS YoY
+24.1%
Gross Margin
+70.2%
Op Margin
-
Net Debt
-$258.65M
Current Ratio
8.64
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology